Firma Lonza Group Ltd., Autor bei Presse-Blog

Lonza Publishes Restated Financials for 2020

29. Juni 2021 Firma Lonza Group Ltd.Finanzen / Bilanzenapm, Biotech, cell, chf, ebit, ebitda, lonza, lonzas, lpbn, lsi, risks, securities, statements, with

Lonza reports restated 2020 financials for sales, EBIT, EBITDA and CORE EBITDA Lonza now provides 2020 financials in the redesigned business structure to reflect divisional performance Prior to the reporting of the Half-Year Results 2021 on 23 July 2021, Lonza Mehr

Lonza Announces Results of the 2021 Annual General Meeting – All Motions Proposed by Board of Directors Accepted

6. Mai 20216. Mai 2021 Firma Lonza Group Ltd.Finanzen / Bilanzenany, bauer, board, chf, covid, dividend, lonza, report, risks, securities, shareholders, statements, steinemann, tax, Trading

47,080,080 shareholders delegated their votes to the independent proxy, representing 63.22% of the share capital Shareholders re-elected all existing members of the Board of Directors Albert M. Baehny was re-elected as Chairman of the Board of Directors for another year A Mehr

Lonza Announces Expansion Plans for Next-Generation Mammalian Manufacturing Facilities in Visp (CH) and Portsmouth (US)

6. Mai 2021 Firma Lonza Group Ltd.Finanzen / Bilanzencell, chf, clinical, drugs, energy, lonza, lonzas, market, new, production, securities, statements, strong, water, with

. Lonza will invest approximately CHF 850 million to build two new state-of-the-art mammalian facilities and respond to customer demand regarding capacity, life cycle management and speed to market A new large-scale facility with the latest manufacturing technology in Visp Mehr

Lonza Announces Construction of a New Small Molecule Manufacturing Complex in Visp

23. April 2021 Firma Lonza Group Ltd.Finanzen / Bilanzenadc, antibody, cancer, cell, cells, chf, clinical, drying, lonza, lonzas, new, patients, project, treatment, with

Lonza will invest CHF 200 million to construct a new manufacturing complex The 2000 m2 complex will include a customer dedicated manufacturing line for antibody-drug conjugate payload molecules The investment is supported by a long-term collaboration and capital contribution with Mehr

Lonza finalise la cession de deux sites à NextPharma

1. April 2021 Firma Lonza Group Ltd.Finanzen / Bilanzences, est, ete, les, lonza, nextpharma, patients, pdg, plein, ploermel, processus, réseau, ses, solutions, une

Finalisation de la vente des sites Lonza de Ploermel (FR) et d’Edimbourg (UK) Un processus de transfert de propriété sans heurts reste une priorité Citation de Gordon Bates, président et responsable de la division Small Molecules, Lonza : "La cession Mehr

Lonza Completes Divestment of Two Sites to NextPharma

1. April 2021 Firma Lonza Group Ltd.Finanzen / Bilanzenbottles, clinical, logistics, lonza, new, nextpharma, packaging, patients, pellets, ploermel, risks, seal, securities, statements, with

Completion of sale of Lonza sites in Ploermel (FR) and Edinburgh (UK) A seamless ownership transfer process remains a priority Quote from Gordon Bates, President and Head of Small Molecules, Lonza: “The strategic divestment of our Ploermel and Edinburgh sites Mehr

Lonza Signs Agreement to Divest Specialty Ingredients Business to Bain Capital and Cinven

9. Februar 2021 Firma Lonza Group Ltd.Finanzen / Bilanzenchf, cinven, composites, customers, electronics, expected, financial, healthcare, ingredients, lonza, lonzas, securities, solutions, strong, with

Lonza Specialty Ingredients to be sold to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion Divestment will allow Lonza to refocus its business as a pure-play partner to the healthcare industry Successful track record of investment Mehr

Lonza Reports Strong 2020 Performance, Driven By Sales Growth in Pharma and Biotech Business

27. Januar 2021 Firma Lonza Group Ltd.Finanzen / Bilanzenbillion, cell, cer, chf, clarity, ebitda, growth, lonza, lonzas, looking, lpbn, lsi, margin, vaccine, vein

Lonza delivers on guidance1 with CHF 4.5 billion sales, 12.0%2 sales growth, and CHF 1.4 billion CORE EBITDA, resulting in a 31.2% margin Lonza results mainly reflect Pharma Biotech & Nutrition (LPBN) performance, as Specialty Ingredients (LSI) is reported as a discontinued Mehr

NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosage Forms

19. Januar 2021 Firma Lonza Group Ltd.Allgemeinbottles, capsule, clinical, lonza, lonzas, market, new, nextpharma, ophthalmic, packaging, patients, pellets, seal, softgels, with

. Agreement initiates process for future acquisition of Lonza sites in Ploermel (FR) and Edinburgh (UK) allowing NextPharma to broaden technology offering into lipid finished dosage forms Centers of excellence employing a total of 390 staff offer expertise in Lipid Mehr

Lonza Announces Customer-Dedicated Suites for Commercialization of Bioconjugates

2. Dezember 20202. Dezember 2020 Firma Lonza Group Ltd.Firmeninternadcs, bioconjugates, bioconjugation, biopark, cancer, cells, ibex, lonza, lonzas, market, patients, power, securities, statements, with

Two new bioconjugation suites to provide high throughput conjugation for the commercialization of antibody-drug conjugates (ADCs) in Lonza’s Ibex®Dedicate 1500m2 of active manufacturing space in addition to established quality control (QC) labs, logistics and other central services Long-term collaboration with Mehr

Autor: Firma Lonza Group Ltd.